@article{Li_Feng_Li_Liu_Yan_Zhu_Li_Li_2023, title={Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer}, url={https://oiccpress.com/international-journal-of-industrial-chemistry/article/evaluation-of-the-efficacy-and-safety-of-folfirinox-or-albumin-bound-paclitaxel-in-combination-with-s-1-in-patients-with-pancreatic-cancer/}, DOI={10.47176/IJIC.13.1.2}, abstractNote={To investigate the clinical efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel (Abraxane) combined with S-1 after radical pancreatic cancer surgery. A total of 133 patients who underwent adjuvant chemotherapy with the FOLFIRINOX (60 cases) or Abraxane combined with S-1 (73 cases) after radical resection pancreatic cancer were screened. According to the follow-up data, recurrence and metastasis, chemotherapy adverse reactions (nausea, vomiting, loss of appetite, leukopenia, thrombocytopenia, anemia, neurotoxicity, diarrhea), survival rate (OS), progression-free survival (PFS) and other indicators were collected to evaluate the efficacy and safety of the two chemotherapy regimens. There was significant difference of metastatic tumor site between both groups (P<0.001). The cases of DCR in the Abraxane + S-1 group were higher compared to the FOLFIRINOX group (P<0.001). The occurrence of adverse events was significantly lower in Abraxane + S-1 group during I-II AE compared with the FOLFIRINOX group. However, there was no significant difference in the AE during III-IV between two groups (P>0.05). The OS (HR=1.872, P=0.005) and PFS (HR=1.931, P=0.003) in Abraxane + S-1 group were significantly higher than those in the FOLFIRINOX group. Adjuvant chemotherapy with Abraxane combined with S-1 regimen in patients with pancreatic cancer resection prolonged OS and PFS, improved DCR, with the overall adverse reactions safe and manageable compared with the FOLFIRINOX regimen.}, journal={International Journal of Industrial Chemistry}, publisher={OICC Press}, author={Li, Luan and Feng, Yuxu and Li, Chenchen and Liu, Siwen and Yan, Fei and Zhu, Jingni and Li, Xiaoyou and Li, Sheng}, year={2023}, month={Nov.}, keywords={Albumin-bound paclitaxel, FOLFIRINOX, Pancreatic cancer, S-1} }